Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

Cancer Letters

Volumn 352, Issue 1, 2014, Pages 15-20

  Izraeli, Shai ^a,b   Shochat, Chen ^a,b,c,d   Tal, Noa ^a,b   Geron, Ifat ^a,b,e  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^d TEL HAI COLLEGE   (Israel)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lymphoblastic leukemia; CRLF2; Interleukin 7 receptor; Risk stratification

Indexed keywords

BCR ABL PROTEIN; CRLF2 PROTEIN; CYTOKINE RECEPTOR; INTERLEUKIN 7 RECEPTOR; JANUS KINASE 2; JANUS KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RNA; STAT PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; CANCER PROGNOSIS; CHEMOSENSITIVITY; CHILD; CHILDHOOD LEUKEMIA; CYTOKINE RELEASE; DIPLOIDY; DOWN SYNDROME; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; NONHUMAN; PATIENT SELECTION; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RNA SEQUENCE; SEX DIFFERENCE; SHORT SURVEY; SIGNAL TRANSDUCTION;

ACUTE LYMPHOBLASTIC LEUKEMIA; CRLF2; INTERLEUKIN 7 RECEPTOR; RISK STRATIFICATION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION;

EID: 84906091502     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.009     Document Type: Review

References (72)

1. Pui C.H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012.
2. Harrison C.J., Haas O., Harbott J., Biondi A., Stanulla M., Trka J., Izraeli S. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the biology and diagnosis committee of the international Berlin-Frankfurt-Munster study group. Br. J. Haematol. 2010, 151:132-142.
3. Izraeli S. Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?. Br. J. Haematol. 2010, 151:119-131.
4. V. Conter, C.R. Bartram, M.G. Valsecchi, A. Schrauder, R. Panzer-Grumayer, A. Moricke, M. Arico, M. Zimmermann, G. Mann, G. De Rossi, M. Stanulla, F. Locatelli, G. Basso, F. Niggli, E. Barisone, G. Henze, W.D. Ludwig, O.A. Haas, G. Cazzaniga, R. Koehler, D. Silvestri, J. Bradtke, R. Parasole, R. Beier, J.J. van Dongen, A. Biondi, M. Schrappe, Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study, Blood 115 (2010) 3206-3214.
5. Borowitz M.J., Devidas M., Hunger S.P., Bowman W.P., Carroll A.J., Carroll W.L., Linda S., Martin P.L., Pullen D.J., Viswanatha D., Willman C.L., Winick N., Camitta B.M. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study. Blood 2008, 111:5477-5485.
6. Luria D., Rosenthal E., Steinberg D., Kodman Y., Safanaiev M., Amariglio N., Avigad S., Stark B., Izraeli S. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytometry B Clin. Cytom. 2010, 78:365-371.
7. M. Bruggemann, A. Schrauder, T. Raff, H. Pfeifer, M. Dworzak, O.G. Ottmann, V. Asnafi, A. Baruchel, R. Bassan, Y. Benoit, A. Biondi, H. Cave, H. Dombret, A.K. Fielding, R. Foa, N. Gokbuget, A.H. Goldstone, N. Goulden, G. Henze, D. Hoelzer, G.E. Janka-Schaub, E.A. Macintyre, R. Pieters, A. Rambaldi, J.M. Ribera, K. Schmiegelow, O. Spinelli, J. Stary, A. von Stackelberg, M. Kneba, M. Schrappe, J.J. van Dongen, in: Standardized MRD quantification in European ALL trials: Proceedings of the Second INTERNATIONAL Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia, 2009.
8. Bourquin J.P., Izraeli S. Where can biology of childhood ALL be attacked by new compounds?. Cancer Treat. Rev. 2010, 36:298-306.
9. Schultz K.R., Bowman W.P., Aledo A., Slayton W.B., Sather H., Devidas M., Wang C., Davies S.M., Gaynon P.S., Trigg M., Rutledge R., Burden L., Jorstad D., Carroll A., Heerema N.A., Winick N., Borowitz M.J., Hunger S.P., Carroll W.L., Camitta B. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J. Clin. Oncol. 2009, 27:5175-5181.
10. Arico M., Schrappe M., Hunger S.P., Carroll W.L., Conter V., Galimberti S., Manabe A., Saha V., Baruchel A., Vettenranta K., Horibe K., Benoit Y., Pieters R., Escherich G., Silverman L.B., Pui C.H., Valsecchi M.G. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J. Clin. Oncol. 1995, 28(2010):4755-4761.
11. Biondi A., Schrappe M., De Lorenzo P., Castor A., Lucchini G., Gandemer V., Pieters R., Stary J., Escherich G., Campbell M., Li C.K., Vora A., Arico M., Rottgers S., Saha V., Valsecchi M.G. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet. Oncol. 2012, 13:936-945.
12. K.R. Schultz, A. Carroll, N.A. Heerema, W.P. Bowman, A. Aledo, W.B. Slayton, H. Sather, M. Devidas, H.W. Zheng, S.M. Davies, P.S. Gaynon, M. Trigg, R. Rutledge, D. Jorstad, N. Winick, M.J. Borowitz, S.P. Hunger, W.L. Carroll, B. Camitta, Long term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031. Leukemia (2014).
13. Ihle J.N., Gilliland D.G. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 2007, 17:8-14.
14. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
15. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
16. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
17. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
18. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., Macintyre E.A., Villeval J.L., Vainchenker W., Berger R., Bernard O.A., Delabesse E., Penard-Lacronique V. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109:2202-2204.
19. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet. Oncol. 2001, 2:429-436.
20. Bercovich D., Ganmore I., Scott L.M., Wainreb G., Birger Y., Elimelech A., Shochat C., Cazzaniga G., Biondi A., Basso G., Cario G., Schrappe M., Stanulla M., Strehl S., Haas O.A., Mann G., Binder V., Borkhardt A., Kempski H., Trka J., Bielorei B., Avigad S., Stark B., Smith O., Dastugue N., Bourquin J.P., Tal N.B., Green A.R., Izraeli S. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
21. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., Tasian S.K., Loh M.L., Su X., Liu W., Devidas M., Atlas S.R., Chen I.M., Clifford R.J., Gerhard D.S., Carroll W.L., Reaman G.H., Smith M., Downing J.R., Hunger S.P., Willman C.L. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2009, 106:9414-9418.
22. Gaikwad A., Rye C.L., Devidas M., Heerema N.A., Carroll A.J., Izraeli S., Plon S.E., Basso G., Pession A., Rabin K.R. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br. J. Haematol. 2009, 144:930-932.
23. Kearney L., Gonzalez De Castro D., Yeung J., Procter J., Horsley S.W., Eguchi-Ishimae M., Bateman C.M., Anderson K., Chaplin T., Young B.D., Harrison C.J., Kempski H., So C.W., Ford A.M., Greaves M. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009, 113:646-648.
24. Blink M., Buitenkamp T.D., van den Heuvel-Eibrink M.M., Danen-van Oorschot A.A., de Haas V., Reinhardt D., Klusmann J.H., Zimmermann M., Devidas M., Carroll A.J., Basso G., Pession A., Hasle H., Pieters R., Rabin K.R., Izraeli S., Zwaan C.M. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 2011, 25:1365-1368.
25. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J., Erber W.N., Kusec R., Larsen T.S., Giraudier S., Le Bousse-Kerdiles M.C., Griesshammer M., Reilly J.T., Cheung B.Y., Harrison C.N., Green A.R. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108:3548-3555.
26. Anand S., Stedham F., Beer P., Gudgin E., Ortmann C.A., Bench A., Erber W., Green A.R., Huntly B.J. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011, 118:177-181.
27. Bandaranayake R.M., Ungureanu D., Shan Y., Shaw D.E., Silvennoinen O., Hubbard S.R. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 2012, 19:754-759.
28. Park L.S., Martin U., Garka K., Gliniak B., Di Santo J.P., Muller W., Largaespada D.A., Copeland N.G., Jenkins N.A., Farr A.G., Ziegler S.F., Morrissey P.J., Paxton R., Sims J.E. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J. Exp. Med. 2000, 192:659-670.
29. Pandey A., Ozaki K., Baumann H., Levin S.D., Puel A., Farr A.G., Ziegler S.F., Leonard W.J., Lodish H.F. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat. Immunol. 2000, 1:59-64.
30. Tonozuka Y., Fujio K., Sugiyama T., Nosaka T., Hirai M., Kitamura T. Molecular cloning of a human novel type I cytokine receptor related to delta1/TSLPR. Cytogenet. Cell Genet. 2001, 93:23-25.
31. Liu Y.J., Soumelis V., Watanabe N., Ito T., Wang Y.H., Malefyt Rde W., Omori M., Zhou B., Ziegler S.F. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 2007, 25:193-219.
32. Lu N., Wang Y.H., Arima K., Hanabuchi S., Liu Y.J. TSLP and IL-7 use two different mechanisms to regulate human CD4+ T cell homeostasis. J. Exp. Med. 2009, 206:2111-2119.
33. Zhou B., Comeau M.R., De Smedt T., Liggitt H.D., Dahl M.E., Lewis D.B., Gyarmati D., Aye T., Campbell D.J., Ziegler S.F. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 2005, 6:1047-1053.
34. Tal N., Shochat C., Geron I., Bercovich D., Izraeli S. Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. Cell Mol. Life Sci. 2013.
35. Chappaz S., Finke D. The IL-7 signaling pathway regulates lymph node development independent of peripheral lymphocytes. J. Immunol. 2010, 184:3562-3569.
36. Siracusa M.C., Saenz S.A., Hill D.A., Kim B.S., Headley M.B., Doering T.A., Wherry E.J., Jessup H.K., Siegel L.A., Kambayashi T., Dudek E.C., Kubo M., Cianferoni A., Spergel J.M., Ziegler S.F., Comeau M.R., Artis D. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 2011, 477:229-233.
37. Reche P.A., Soumelis V., Gorman D.M., Clifford T., Liu M., Travis M., Zurawski S.M., Johnston J., Liu Y.J., Spits H., de Waal Malefyt R., Kastelein R.A., Bazan J.F. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J. Immunol. 2001, 167:336-343.
38. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., Shiloh R., Iacobucci I., Shochat C., Zeligson S., Cario G., Stanulla M., Strehl S., Russell L.J., Harrison C.J., Bornhauser B., Yoda A., Rechavi G., Bercovich D., Borkhardt A., Kempski H., te Kronnie G., Bourquin J.P., Domany E., Izraeli S. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the international BFM study group. Blood 2010, 115:1006-1017.
39. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., Ma J., Coustan-Smith E., Harvey R.C., Willman C.L., Mikhail F.M., Meyer J., Carroll A.J., Williams R.T., Cheng J., Heerema N.A., Basso G., Pession A., Pui C.H., Raimondi S.C., Hunger S.P., Downing J.R., Carroll W.L., Rabin K.R. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 2009, 41:1243-1246.
40. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., Chandrasekaran T., Chapiro E., Gesk S., Griffiths M., Guttery D.S., Haferlach C., Harder L., Heidenreich O., Irving J., Kearney L., Nguyen-Khac F., Machado L., Minto L., Majid A., Moorman A.V., Morrison H., Rand V., Strefford J.C., Schwab C., Tonnies H., Dyer M.J., Siebert R., Harrison C.J. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
41. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., West N., Xiao Y., Brown J.R., Mitsiades C., Sattler M., Kutok J.L., DeAngelo D.J., Wadleigh M., Piciocchi A., Dal Cin P., Bradner J.E., Griffin J.D., Anderson K.C., Stone R.M., Ritz J., Foa R., Aster J.C., Frank D.A., Weinstock D.M. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2010, 107:252-257.
42. Attarbaschi A., Morak M., Cario G., Cazzaniga G., Ensor H.M., te Kronnie T., Bradtke J., Mann G., Vendramini E., Palmi C., Schwab C., Russell L.J., Schrappe M., Conter V., Mitchell C.D., Strehl S., Zimmermann M., Potschger U., Harrison C.J., Stanulla M., Panzer-Grumayer R., Haas O.A., Moorman A.V. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br. J. Haematol. 2012, 158:772-777.
43. Buitenkamp T.D., Pieters R., Gallimore N.E., van der Veer A., Meijerink J.P., Beverloo H.B., Zimmermann M., de Haas V., Richards S.M., Vora A.J., Mitchell C.D., Russell L.J., Schwab C., Harrison C.J., Moorman A.V., van den Heuvel-Eibrink M.M., den Boer M.L., Zwaan C.M. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012.
44. Cario G., Zimmermann M., Romey R., Gesk S., Vater I., Harbott J., Schrauder A., Moericke A., Izraeli S., Akasaka T., Dyer M.J., Siebert R., Schrappe M., Stanulla M. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
45. Chen I.M., Harvey R.C., Mullighan C.G., Gastier-Foster J., Wharton W., Kang H., Borowitz M.J., Camitta B.M., Carroll A.J., Devidas M., Pullen D.J., Payne-Turner D., Tasian S.K., Reshmi S., Cottrell C.E., Reaman G.H., Bowman W.P., Carroll W.L., Loh M.L., Winick N.J., Hunger S.P., Willman C.L. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a children's oncology group study. Blood 2012, 119:3512-3522.
46. Ensor H.M., Schwab C., Russell L.J., Richards S.M., Morrison H., Masic D., Jones L., Kinsey S.E., Vora A.J., Mitchell C.D., Harrison C.J., Moorman A.V. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117:2129-2136.
47. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., Kang H., Liu W., Dobbin K.K., Smith M.A., Carroll W.L., Devidas M., Bowman W.P., Camitta B.M., Reaman G.H., Hunger S.P., Downing J.R., Willman C.L. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
48. Moorman A.V., Schwab C., Ensor H.M., Russell L.J., Morrison H., Jones L., Masic D., Patel B., Rowe J.M., Tallman M., Goldstone A.H., Fielding A.K., Harrison C.J., Translocations IGH@ IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 2012.
49. Morak M., Attarbaschi A., Fischer S., Nassimbeni C., Grausenburger R., Bastelberger S., Krentz S., Cario G., Kasper D., Schmitt K., Russell L.J., Potschger U., Stanulla M., Eckert C., Mann G., Haas O.A., Panzer-Grumayer R. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood 2012, 120:5134-5142.
50. Palmi C., Vendramini E., Silvestri D., Longinotti G., Frison D., Cario G., Shochat C., Stanulla M., Rossi V., Di Meglio A.M., Villa T., Giarin E., Fazio G., Leszl A., Schrappe M., Basso G., Biondi A., Izraeli S., Conter V., Valsecchi M.G., Cazzaniga G., Te Kronnie G. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012, 26:2245-2253.
51. van der Veer A., Waanders E., Pieters R., Willemse M.E., Van Reijmersdal S.V., Russell L.J., Harrison C.J., Evans W.E., van der Velden V.H., Hoogerbrugge P.M., Van Leeuwen F., Escherich G., Horstmann M.A., Mohammadi L., Khankahdani, Rizopoulos D., De Groot-Kruseman H.A., Sonneveld E., Kuiper R.P., Den Boer M.L. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013.
52. Tasian S.K., Doral M.Y., Borowitz M.J., Wood B.L., Chen I.M., Harvey R.C., Gastier-Foster J.M., Willman C.L., Hunger S.P., Mullighan C.G., Loh M.L. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 2012, 120:833-842.
53. Hornakova T., Chiaretti S., Lemaire M.M., Foa R., Ben R., Abdelali, Asnafi V., Tartaglia M., Renauld J.C., Knoops L. ALL-associated JAK1 mutations confer hypersensitivity to the anti-proliferative effect of type I interferon. Blood 2010.
54. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., Chen S.C., Payne-Turner D., Churchman M.L., Harvey R.C., Chen X., Kasap C., Yan C., Becksfort J., Finney R.P., Teachey D.T., Maude S.L., Tse K., Moore R., Jones S., Mungall K., Birol I., Edmonson M.N., Hu Y., Buetow K.E., Chen I.M., Carroll W.L., Wei L., Ma J., Kleppe M., Levine R.L., Garcia-Manero G., Larsen E., Shah N.P., Devidas M., Reaman G., Smith M., Paugh S.W., Evans W.E., Grupp S.A., Jeha S., Pui C.H., Gerhard D.S., Downing J.R., Willman C.L., Loh M., Hunger S.P., Marra M.A., Mullighan C.G. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
55. Gery S., Cao Q., Gueller S., Xing H., Tefferi A., Koeffler H.P. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J. Leukoc. Biol. 2009, 85:957-965.
56. Gery S., Gueller S., Chumakova K., Kawamata N., Liu L., Koeffler H.P. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007, 110:3360-3364.
57. Li Y., He X., Schembri-King J., Jakes S., Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J. Immunol. 2000, 164:5199-5206.
58. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005, 105:4604-4612.
59. Takaki S., Sauer K., Iritani B.M., Chien S., Ebihara Y., Tsuji K., Takatsu K., Perlmutter R.M. Control of B cell production by the adaptor protein lnk. Definition of a conserved family of signal-modulating proteins. Immunity 2000, 13:599-609.
60. Takaki S., Tezuka Y., Sauer K., Kubo C., Kwon S.M., Armstead E., Nakao K., Katsuki M., Perlmutter R.M., Takatsu K. Impaired lymphopoiesis and altered B cell subpopulations in mice overexpressing Lnk adaptor protein. J. Immunol. 2003, 170:703-710.
61. Perez-Garcia A., Ambesi-Impiombato A., Hadler M., Rigo I., Leduc C.A., Kelly K., Jalas C., Paietta E., Racevskis J., Rowe J.M., Tallman M.S., Paganin M., Basso G., Tong W., Chung W.K., Ferrando A.A. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 2013.
62. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., Te Kronnie G., Cario G., Cazzaniga G., Kulozik A.E., Stanulla M., Schrappe M., Biondi A., Basso G., Bercovich D., Muckenthaler M.U., Izraeli S. Gain-of-function mutations in interleukin-7 receptor-{alpha} (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 2011, 208:901-908.
63. Zenatti P.P., Ribeiro D., Li W., Zuurbier L., Silva M.C., Paganin M., Tritapoe J., Hixon J.A., Silveira A.B., Cardoso B.A., Sarmento L.M., Correia N., Toribio M.L., Kobarg J., Horstmann M., Pieters R., Brandalise S.R., Ferrando A.A., Meijerink J.P., Durum S.K., Yunes J.A., Barata J.T. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 2011, 43:932-939.
64. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., Easton J., Chen X., Wang J., Rusch M., Lu C., Chen S.C., Wei L., Collins-Underwood J.R., Ma J., Roberts K.G., Pounds S.B., Ulyanov A., Becksfort J., Gupta P., Huether R., Kriwacki R.W., Parker M., McGoldrick D.J., Zhao D., Alford D., Espy S., Bobba K.C., Song G., Pei D., Cheng C., Roberts S., Barbato M.I., Campana D., Coustan-Smith E., Shurtleff S.A., Raimondi S.C., Kleppe M., Cools J., Shimano K.A., Hermiston M.L., Doulatov S., Eppert K., Laurenti E., Notta F., Dick J.E., Basso G., Hunger S.P., Loh M.L., Devidas M., Wood B., Winter S., Dunsmore K.P., Fulton R.S., Fulton L.L., Hong X., Harris C.C., Dooling D.J., Ochoa K., Johnson K.J., Obenauer J.C., Evans W.E., Pui C.H., Naeve C.W., Ley T.J., Mardis E.R., Wilson R.K., Downing J.R., Mullighan C.G. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
65. Tasian S.K., Doral M.Y., Wood B.L., Borowitz M.J., Collins-Underwood J.R., Harvey R.C., Sakamoto K.M., Willman C.L., Hunger S.P., Mullighan C.G., Loh M.L. Thymic stromal lymphopoietin stimulation of pediatric acute lymphoblastic leukemias with CRLF2 alterations induces JAK/STAT and PI3K phosphosignaling. Blood 2010, 116:182-183.
66. Maude S.L., Tasian S.K., Vincent T., Hall J.W., Sheen C., Roberts K.G., Seif A.E., Barrett D.M., Chen I.M., Collins J.R., Mullighan C.G., Hunger S.P., Harvey R.C., Willman C.L., Fridman J.S., Loh M.L., Grupp S.A., Teachey D.T. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120:3510-3518.
67. Weigert O., Lane A.A., Bird L., Kopp N., Chapuy B., van Bodegom D., Toms A.V., Marubayashi S., Christie A.L., McKeown M., Paranal R.M., Bradner J.E., Yoda A., Gaul C., Vangrevelinghe E., Romanet V., Murakami M., Tiedt R., Ebel N., Evrot E., De Pover A., Regnier C.H., Erdmann D., Hofmann F., Eck M.J., Sallan S.E., Levine R.L., Kung A.L., Baffert F., Radimerski T., Weinstock D.M. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 2012, 209:259-273.
68. Cheng D.T., Ma C., Niewoehner J., Dahl M., Tsai A., Zhang J., Gonsiorek W., Apparsundaram S., Pashine A., Ravindran P., Jung J., Hang J., Allard J., Bitter H., Tribouley C., Narula S., Wilson S., Fuentes M.E. Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma. J. Allergy Clin. Immunol. 2013, 132:455-462.
69. Lee L.F., Logronio K., Tu G.H., Zhai W., Ni I., Mei L., Dilley J., Yu J., Rajpal A., Brown C., Appah C., Chin S.M., Han B., Affolter T., Lin J.C. Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc. Natl. Acad. Sci. USA 2012, 109:12674-12679.
70. Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet 2013, 381:1943-1955.
71. Den Boer M.L., van Slegtenhorst M., De Menezes R.X., Cheok M.H., Buijs-Gladdines J.G., Peters S.T., Van Zutven L.J., Beverloo H.B., Van der Spek P.J., Escherich G., Horstmann M.A., Janka-Schaub G.E., Kamps W.A., Evans W.E., Pieters R. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet. Oncol. 2009, 10:125-134.
72. Perez-Andreu V., Roberts K.G., Harvey R.C., Yang W., Cheng C., Pei D., Xu H., Gastier-Foster J., S.E., Lim J.Y., Chen I.M., Fan Y., Devidas M., Borowitz M.J., Smith C., Neale G., Burchard E.G., Torgerson D.G., Klussmann F.A., Villagran C.R., Winick N.J., Camitta B.M., Raetz E., Wood B., Yue F., Carroll W.L., Larsen E., Bowman W.P., Loh M.L., Dean M., Bhojwani D., Pui C.H., Evans W.E., Relling M.V., Hunger S.P., Willman C.L., Mullighan C.G., Yang J.J. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 2013, 45:1494-1498.